*  Image-Guided Hypofractionated Radiation Therapy With Stereotactic Body Radiation Therapy Boost and Combination Chemotherapy in...
The primary end point is to reach the maximum tolerated dose or a total of 75 Gy, whichever comes first, by escalating the ... I. To determine the dose-limiting toxicity, if the MTD is reached. ... I. To determine the maximum tolerated dose (MTD) using hypofractionated RT in patients with stage II-III NSCLC. ... To determine the maximal tolerated dose using hypofractionated radiotherapy in patients with stage II-III non small cell lung ...
  https://clinicaltrials.gov/ct2/show/NCT01345851?cond=%22Carcinoma%2C+Non-Small-Cell+Lung%22&rank=3
*  Search of: desmoid tumors - List Results - ClinicalTrials.gov
Dose-limiting toxicities and maximum tolerated dose. *Pharmacology and pharmacokinetics. *Acetylation of histones in peripheral ... Toxicity as Assessed by the National Cancer Institute Common Toxicity Terminology for Adverse Events v3.0 ... A Dose Escalation Study of OMP-54F28 in Subjects With Solid Tumors. *Solid Tumors ... a zip file of the full study records in XML for all studies in the search results table (max 10000) ...
  https://clinicaltrials.gov/ct2/results?term=desmoid+tumors&Search=Search
*  Study of GC33 and Sorafenib in Combination in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma) - Full Text View -...
Dose limiting toxicity and maximum tolerated dose [ Time Frame: Continuous ]. Secondary Outcome Measures : *RECIST criteria ( ... Enrollment will proceed until a maximum tolerated dose (MTD) and a recommended Phase II dose has been established. ... This phase I trial is studying the safety and best dose of GC33 and Sorafenib in combination in patients with advanced or ... This is a Phase I open-label dose escalation study of GC33 in combination with Sorafenib in patients with advanced or ...
  https://clinicaltrials.gov/show/NCT00976170
*  Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment
To determine the dose-limiting toxicities and maximum tolerated doses of bortezomib and. temozolomide in patients with ... patients in both groups receive escalating doses of both study drugs until the maximum. tolerated doses are determined.. All ... Maximum Age:. N/A Enrollment Status:. Not Enrolling. Gender:. Both. Conditions:. Brain and Central Nervous System Tumors, ... dose for at least 1 week. Exclusion criteria:. - Patients enrolled on another clinical trial. - HIV-positive patients on ...
  http://www.knowcancer.com/cancer-trials/NCT00544284/
*  Cytotoxic T-Lymphocytes for the Prophylaxis of Cytomegalovirus After Allogeneic Stem Cell Transplant
safety, toxicity and maximum tolerated dose (MTD). Outcome Time Frame:. 30 days ... receive the dose of CMV CTL cells on or after day 30 following their transplant if they. agree and are well enough. We will not ... initial dose of CMV CTL cells the patient develops a viral infection, then they may be. eligible to receive one additional ... If the CMV levels in the blood continue to rise after the dose of T cells then. the patient will receive treatment with ...
  http://www.knowcancer.com/cancer-trials/NCT00078533/
*  Search of: MLLT3 - List Results - ClinicalTrials.gov
Dose-limiting toxicity and maximum tolerated dose of tipifarnib and bortezomib. *Changes in apoptotic protein expression (Bim, ... Maximum tolerated dose of veliparib, determined as the highest dose level where 0/3 or 1/6 experience DLT, measured according ... Maximum-tolerated dose of azacitidine that can be safely combined with mitoxantrone hydrochloride and etoposide chemotherapy ... Maximum tolerated dose of belinostat in combination with azacitidine. *Changes in pharmacodynamic variables (target gene ...
  https://clinicaltrials.gov/ct2/results?term=MLLT3
*  Search of: 'PDGFRB-associated chronic eosinophilic leukemia' OR 'hypereosinophilic syndrome' - List Results - ClinicalTrials.gov
To determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of AMN107 as a single agent when administered as ... Dose-limiting toxicity and maximum tolerated dose of tipifarnib and bortezomib. *Changes in apoptotic protein expression (Bim, ... Maximum-tolerated dose as assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE ... Maximum-tolerated dose of azacitidine that can be safely combined with mitoxantrone hydrochloride and etoposide chemotherapy ...
  https://clinicaltrials.gov/ct2/results?cond=%22PDGFRB-associated+chronic+eosinophilic+leukemia%22+OR+%22hypereosinophilic+syndrome%22&show_rss=Y
*  Study Evaluating TRU-015 in B-Cell Non-Hodgkin's Lymphoma - Full Text View - ClinicalTrials.gov
Maximum Tolerated Dose: dose-limiting toxicities. Efficacy: disease response and progression status per International Response ... Once a maximum tolerated dose (MTD) is confirmed or maximum dose to be studied is determined to be safe and well tolerated, an ... Safety of an escalating dose of 4 weekly infusions of TRU-015 will be evaluated in subjects with relapsed NHL (see inclusion ... A Phase 1/2 Dose Escalation Study of TRU-015 in Subjects With Relapsed or Refractory B Cell Non-Hodgkin's Lymphoma. ...
  https://clinicaltrials.gov/show/NCT00521638
*  Search of: 'neurofibromatosis type 1' - List Results - ClinicalTrials.gov
Maximum tolerated dose, chronic toxicity, pharmacokinetics and pharmacodynamics.. *3D MRI of plexiform neurofibromas, ... a zip file of the full study records in XML for all studies in the search results table (max 10000) ... Number of Patients With Adverse Events Assessed by Common Toxicity Criteria for Adverse Events (CTCAE) V.04 ...
  https://clinicaltrials.gov/ct2/results?cond=%22neurofibromatosis%20type%201%22
*  Search of: Neurofibromatosis Type 1 | 'neurofibromatosis type 2' OR 'neurofibromatosis' - List Results - ClinicalTrials.gov
Maximum tolerated dose, chronic toxicity, pharmacokinetics and pharmacodynamics.. *3D MRI of plexiform neurofibromas, ... a zip file of the full study records in XML for all studies in the search results table (max 10000) ... To describe the toxicities of selumetinib in patients with NF1- mutated GIST. ... Number of Patients With Adverse Events Assessed by Common Toxicity Criteria for Adverse Events (CTCAE) V.04 ...
  https://clinicaltrials.gov/ct2/results?term=Neurofibromatosis+Type+1&cond=%22neurofibromatosis+type+2%22+OR+%22neurofibromatosis%22
*  Vitamin D-related Therapies in Prostate Cancer | SpringerLink
Patients were evaluated for toxicity, maximum tolerated dose (MTD), schedule effects, and PSA response. Data from these studies ... Davies M: High-dose vitamin D therapy: Indications, benefits and hazards. In: Walter P, Brubacher G, Stahelin H (eds) Elevated ... Trump DL, Serafine S, Brufsky A, Potter D, Johnson CS: High dose calcitriol (1,25(OH)2 vitamin D3) + dexamethasone in androgen ... Johnson CS, Egorin MJ, Zuhowski R, Parise R, Cappozolli M, Belani CP, Long GS, Muindi J, Trump DL: Effects of high dose ...
  https://link.springer.com/article/10.1023%2FA%3A1020836226594
*  Search of: 'Brain tumor adult' - List Results - ClinicalTrials.gov
Number of Dose Limiting Toxicity to Determine Maximum Tolerated Dose (MTD) of BMS-247550 in Patients With Recurrent or ... Maximum Tolerated Dose of Tandutinib Defined by Dose Limiting Toxicities (Phase 1) ... Establish maximum tolerated dose and define toxicity profile. *Six month progression free survival defined as the proportion of ... Maximally tolerated dose of the each combination agent combined with a fixed dose of BAY 43-9006 determined by dose-limiting ...
  https://clinicaltrials.gov/ct2/results?cond=%22Brain+tumor+adult%22
*  A Study to Determine Safety, Pharmacokinetics and Pharmacodynamics of Intravenous TKM 080301 in Neuroendocrine Tumors (NET) and...
Determine dose-limiting toxicities and maximum tolerated dose of TKM-080301 [ Time Frame: 6 months ]. ... After the determination of the maximum tolerated dose this dose will be utilized in an expansion cohort or subjects with ... Unresolved toxicities (, Grade 1) of previous chemotherapy,. *Patients with primary tumors of the central nervous system (CNS), ... This study will be a Phase I/II, open-label, non-randomized, dose-finding trial conducted at multiple clinical centers. The ...
  https://clinicaltrials.gov/ct2/show/NCT01262235?term=TKM-080301&rank=1
*  Phase 1/2, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis - Full Text View -...
Dose limiting toxicity and maximum tolerated dose. *Maximum tolerated dose [ Time Frame: 28 day cycles, up to 1 year; beyond 1 ... The starting dose will be 0.5 mg/kg. Dose escalation will continue until the the maximum tolerated dose is determined for ... The purpose of the dose escalation phase of the study is to determine the maximum tolerated dose/Phase 2 recommended dose of ... Dose escalation study to determine the maximum tolerated dose of NEOD001 in approximately 30 subjects with AL amyloidosis. ...
  https://clinicaltrials.gov/ct2/show/NCT01707264?recr=Open&cond=%22Amyloidosis%22&rank=11
*  Search of: ALT-803 cancer - List Results - ClinicalTrials.gov
Dose-limiting toxicities and maximum tolerated dose of the ETBX-011 plus ALT-803 combination treatment. (Phase 1b) ... Maximal tolerated or tested dose (MT/TD) of CIML-NK cells (Phase I) ... Presence or absence of a dose limiting toxicity (DLT) of ALT-803 in combination with Nivolumab ... To evaluate the effect of escalating doses of ALT-803. 26. All. 18 Years and older (Adult, Senior). NCT01946789. CITN06-ALT-803 ...
  https://clinicaltrials.gov/ct2/results?term=ALT-803+cancer
*  Gemcitabine, Carboplatin, and Lenalidomide for Treatment of Advanced/Metastatic Urothelial Cancer and Other Solid Tumors - Full...
Dose limiting toxicity [ Time Frame: Maximum Tolerated Dose ]. Eligibility Criteria. Go to Top of Page Study Description Study ... Dose Limiting Toxicity. Urethra Cancer. Carcinoma of the Bladder. Cancer of the Renal Pelvis. Ureter Cancer. Urethral Cancer. ... Dose Escalation cohort only. - Adult patients with histologic documentation of an advanced solid tumor for whom gemcitabine and ... Escalating Doses starting at 2.5 po daily up to 25 mg po daily until MTD is reached. ...
  https://clinicaltrials.gov/show/NCT01352962
*  Search of: 'Adrenocortical carcinoma' - List Results - ClinicalTrials.gov
Maximum tolerated dose determined by dose limiting toxicities defined as any toxicity in the first course evaluated according ... Frequency of dose-limiting toxicity and determination of maximum tolerated dose. *Area under the plasma concentration versus ... Maximum tolerated dose (MTD) determined according to dose-limiting toxicities (DLTs) graded using Common Terminology Criteria ... Maximum Tolerated Dose (MTD) of continuous hyperthermic peritoneal perfusion (CHPP) with cisplatin in children with peritoneal ...
  https://clinicaltrials.gov/ct2/results?cond=%22Adrenocortical+carcinoma%22
*  Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML - Full Text View -...
Dose-limiting Toxicity and Maximum Tolerated Dose of Vorinostat (Phase I) [ Time Frame: 42 days ]. *Efficacy Defined as Best ... I. Determine the vorinostat dose with the most favorable efficacy and toxicity when combined with azacitidine and GO. ... Experimental: Phase 1 - Dose Finding Varying schedules and dose levels of vorinostat, azacitidine and gemtuzumab ozogamicin. ... Experimental: Phase 2 - Treatment at Selected Dose Vorinostat 400 mg/day on days 1-9, azacitidine 75 mg/m2/day on days 1-7, ...
  https://clinicaltrials.gov/ct2/show/NCT00895934?cond=%22Acute+myelomonocytic+leukemia%22&rank=15
*  Monoclonal Antibody F19 in Treating Patients With Advanced or Metastatic Cancer - Full Text View - ClinicalTrials.gov
Determine the dose limiting toxicity and maximum tolerated dose of this drug in these patients. III. Measure induction titers ... The dose of BIBH-1 is escalated in cohorts of 3-6 patients until the maximum tolerated dose (MTD) is determined. The MTD is ... defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose limiting toxicity. Patients are followed ... OBJECTIVES: I. Identify the toxicity associated with increasing doses of monoclonal antibody F19 (BIBH-1) administered weekly ...
  https://clinicaltrials.gov/ct2/show/NCT00004042
*  Acute Myeloid Leukemia Clinical Research | OSUCCC - James
Define the specific toxicities, maximum tolerated dose and dose-limiting toxicity of this combination ... and relapsed AML patients to determine safety and preliminary efficacy and to establish the recommended Phase II dose ...
  https://cancer.osu.edu/research-and-education/clinical-research/hematologic-malignancies/acute-myeloid-leukemia
*  FAU in Treating Patients With Advanced Solid Tumors or Lymphoma - Full Text View - ClinicalTrials.gov
Maximum tolerated dose, defined as the dose at which no more than 1/6 patients develops dose-limiting toxicity, graded by NCI ... To determine the dose-limiting toxicity and maximum tolerated dose (MTD) of FAU in these patients. ... Accessible tumor tissue available (for patients enrolled in the expanded maximum tolerated dose [MTD] cohort) ... This phase I trial is studying the side effects and best dose of FAU in treating patients with advanced solid tumors or ...
  https://clinicaltrials.gov/ct2/show/NCT00769288?recr=Open&cond=%22Mycoses%22&rank=18
*  A Study of RO5045337 [RG7112] in Patients With Hematologic Neoplasms. - Full Text View - ClinicalTrials.gov
Maximum tolerated dose/Dose-limiting toxicities [ Time Frame: approximately 4.5 years ]. *Safety: Incidence of adverse events ... This study will determine the maximum tolerated dose of RO5045337 and the optimal associated 4 weekly dosing schedule of ... An Open Label Study to Investigate the Maximum Tolerated Dose of RO5045337 in Patients With Acute Myelogenous Leukemia (AML), ... Subsequent cohorts of patients will receive dose escalations, and possible changes in dosing schedule, based on tolerability ...
  https://clinicaltrials.gov/ct2/show/NCT00623870
*  Search of: inv(16) | 'Acute monoblastic leukemia' - List Results - ClinicalTrials.gov
Dose-limiting Toxicity and Maximum Tolerated Dose of Vorinostat (Phase I). *Efficacy Defined as Best Response Achieved During ... Dose-limiting toxicity and maximum tolerated dose of tipifarnib and bortezomib. *Changes in apoptotic protein expression (Bim, ... Maximum tolerated dose determined by dose-limiting toxicities graded according to NCI-CTC version 3.0 ... Maximum tolerated dose of veliparib, determined as the highest dose level where 0/3 or 1/6 experience DLT, measured according ...
  https://clinicaltrials.gov/ct2/results?term=inv%2816%29&cond=%22Acute+monoblastic+leukemia%22
*  Search of: 'Acute promyelocytic leukemia' - List Results - ClinicalTrials.gov
Maximum tolerated dose and dose-limiting toxicity of ixabepilone. *Toxicity spectrum. *Plasma pharmacokinetics ... Determine the maximum tolerated dose of topotecan when combined with etoposide in patients with relapsed or refractory acute ... AEG35156 in Combination With High-dose Cytarabine and Idarubicin in AML Following Failure of a Single Standard Dose Cytarabine ... rate and duration of high-dose cytarabine and idarubicin in AML following failure of a single standard dose cytarabine based ...
  https://clinicaltrials.gov/ct2/results?cond=%22Acute+promyelocytic+leukemia%22&pg=2
*  PS-341 in Treating Patients With Advanced Cancer - Full Text View - ClinicalTrials.gov
Determine the maximum tolerated dose and toxicity of PS-341 in patients with advanced malignancies. ... Cohorts of 3-6 patients receive escalating doses of PS-341 until the maximum tolerated dose (MTD) is determined. The MTD is ... Patients with B-cell lymphoproliferative disorders and a leukemic phase are eligible once the maximum tolerated dose is ... defined as the dose preceding that at which 1 of 3-4 or 2 of 6 patients experience dose-limiting toxicity. ...
  https://clinicaltrials.gov/ct2/show/NCT00006362